Oculis Holding AG

Oculis Holding AG is a global biopharmaceutical company dedicated to saving sight and improving eye care through breakthrough innovations. Headquartered in Zug, Switzerland, the company also maintains operations in the U.S., Iceland, France, and Hong Kong.

The company's late-stage clinical pipeline focuses on addressing significant unmet medical needs in ophthalmology and neuro-ophthalmology. Key product candidates include OCS-01, a topical retinal candidate for diabetic macular edema (DME); Licaminlimab (formerly OCS-02), a topical biologic candidate for dry eye disease (DED); and Privosegtor (formerly OCS-05), a disease-modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders such as glaucoma and diabetic retinopathy. Oculis leverages its proprietary OPTIREACH® solubilizing formulation technology to develop these treatments.

Oculis is a publicly traded company, having gone public on March 3, 2023, through a SPAC merger with European Biotech Acquisition Corp. Recent developments include the completion of the last patient visit in the Phase 3 DIAMOND program for OCS-01 eye drops for DME, with topline results anticipated in June 2026 and a potential New Drug Application (NDA) submission in Q4 2026. Additionally, Privosegtor has received Breakthrough Therapy designation from the U.S. FDA and Priority Medicines (PRIME) designation from the European Medicines Agency for optic neuritis. The company is led by CEO Riad Sherif, with recent executive appointments including Snehal Shah as President of R&D and Katie Kazem as Chief Legal Officer.

Latest updates

Oculis Highlights Pipeline Progress Amidst DME Treatment Gap

Event summary

  • Oculis is presenting data at the ARVO 2026 Annual Meeting and Eyecelerator, focusing on its late-stage pipeline for ophthalmic and neuro-ophthalmic diseases.
  • The DME AWARE Delphi Study, sponsored by Oculis, revealed a consensus need for non-invasive treatments for diabetic macular edema (DME).
  • Post-hoc analysis of the ACUITY trial suggests Privosegtor may reduce retinal ganglion cell loss and improve visual acuity in optic neuritis patients.
  • Oculis anticipates topline results for OCS-01 eye drops (for DME) in June 2026, following completion of the Phase 3 DIAMOND program in April 2026.
  • Privosegtor has received Breakthrough Therapy designation from the FDA and PRIME designation from the EMA for optic neuritis.

The big picture

The DME AWARE study underscores a significant unmet need for less invasive treatments in a market estimated to affect 53 million people by 2040. Oculis’ OCS-01, if successful, could represent a paradigm shift away from invasive procedures like intravitreal injections, potentially capturing a substantial share of the market. The company’s focus on neuro-ophthalmology with Privosegtor also positions it to address a rare but high-value therapeutic area with limited competition.

What we're watching

Clinical Adoption
The acceptance of OCS-01 as a non-invasive DME treatment will depend heavily on the clinical data presented and its perceived efficacy compared to existing therapies, potentially disrupting the intravitreal injection market.
Regulatory Risk
The FDA and EMA’s review of Privosegtor’s Breakthrough Therapy and PRIME designations, respectively, will be critical; any unexpected requests for additional data could significantly delay approval and commercialization.
Pipeline Execution
Oculis’ ability to advance Licaminlimab through its registrational program, PREDICT, will be a key indicator of the company’s overall pipeline management capabilities and its ability to deliver on its ambitious goals.
CID: 2706